-
1
-
-
20144363192
-
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
-
DOI 10.1016/S0140-6736(05)71142-9
-
Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365:1054-1061. (Pubitemid 40386783)
-
(2005)
Lancet
, vol.365
, Issue.9464
, pp. 1054-1061
-
-
Baxter, E.J.1
Scott, L.M.2
Campbell, P.J.3
East, C.4
Fourouclas, N.5
Swanton, S.6
Vassiliou, G.S.7
Bench, A.J.8
Boyd, E.M.9
Curtin, N.10
Scott, M.A.11
Erber, W.N.12
Avis, T.13
Barthorpe, A.14
Bignell, G.15
Blow, M.16
Brackenbury, L.17
Buck, G.18
Clegg, S.19
Clements, J.20
Cole, J.21
Davies, H.22
Edkins, S.23
Gray, K.24
Gorton, M.25
O'Meara, S.26
Halliday, K.27
Harrison, R.28
Haynes, W.29
Hills, K.30
Hunter, C.31
Jones, D.32
Kosmidou, V.33
Laman, R.34
Lugg, R.35
Parker, A.36
Perry, J.37
Petty, R.38
Small, A.39
Solomon, H.40
Stephens, P.41
Stephens, Y.42
Stevens, C.43
Smith, R.44
Tarpey, P.45
Tofts, C.46
Varian, J.47
West, S.48
Widaa, S.49
Bamford, S.50
Butler, A.51
Dawson, E.52
Dicks, E.53
Edwards, K.54
Forbes, S.55
Greenman, C.56
Hinton, J.57
Menzies, A.58
Raine, K.59
Shepherd, R.60
Teague, J.61
Yates, A.62
Wooster, R.63
Futreal, A.64
Stratton, M.65
Green, A.R.66
more..
-
2
-
-
21344467318
-
Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders
-
DOI 10.1182/blood-2005-03-1320
-
Jones AV, Kreil S, Zoi K, et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 2005;106:2162-2168. (Pubitemid 41291734)
-
(2005)
Blood
, vol.106
, Issue.6
, pp. 2162-2168
-
-
Jones, A.V.1
Kreil, S.2
Zoi, K.3
Waghorn, K.4
Curtis, C.5
Zhang, L.6
Score, J.7
Seear, R.8
Chase, A.J.9
Grand, F.H.10
White, H.11
Zoi, C.12
Loukopoulos, D.13
Terpos, E.14
Vervessou, E.-C.15
Schultheis, B.16
Emig, M.17
Ernst, T.18
Lengfelder, E.19
Hehlmann, R.20
Hochhaus, A.21
Oscier, D.22
Silver, R.T.23
Reiter, A.24
Cross, N.C.P.25
more..
-
3
-
-
17644424955
-
A gain-of-function mutation of JAK2 in myeloproliferative disorders
-
DOI 10.1056/NEJMoa051113
-
Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352:1779-1790. (Pubitemid 40570926)
-
(2005)
New England Journal of Medicine
, vol.352
, Issue.17
, pp. 1779-1790
-
-
Kralovics, R.1
Passamonti, F.2
Buser, A.S.3
Teo, S.-S.4
Tiedt, R.5
Passweg, J.R.6
Tichelli, A.7
Cazzola, M.8
Skoda, R.C.9
-
4
-
-
17844383458
-
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
-
DOI 10.1038/nature03546
-
James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434:1144-1148. (Pubitemid 40663494)
-
(2005)
Nature
, vol.434
, Issue.7037
, pp. 1144-1148
-
-
James, C.1
Ugo, V.2
Le Couedic, J.-P.3
Staerk, J.4
Delhommeau, F.5
Lacout, C.6
Garcon, L.7
Raslova, H.8
Berger, R.9
Bennaceur-Griscelli, A.10
Villeval, J.L.11
Constantinescu, S.N.12
Casadevall, N.13
Vainchenker, W.14
-
5
-
-
38349101871
-
Classif cation and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms
-
Teferi A, Vardiman JW. Classif cation and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2007;22:14-22.
-
(2007)
Leukemia
, vol.22
, pp. 14-22
-
-
Teferi, A.1
Vardiman, J.W.2
-
6
-
-
84993810398
-
Update on JAK2 inhibitors in myeloproliferative neoplasm
-
Chan D, Koren-Michowitz M. Update on JAK2 inhibitors in myeloproliferative neoplasm. Ther Adv Hematol 2011;2:61-71.
-
(2011)
Ther Adv Hematol
, vol.2
, pp. 61-71
-
-
Chan, D.1
Koren-Michowitz, M.2
-
7
-
-
33749358349
-
Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia
-
DOI 10.1182/blood-2006-04-018259
-
Scott LM, Scott MA, Campbell PJ, et al. Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia. Blood 2006;108:2435-2437. (Pubitemid 44497530)
-
(2006)
Blood
, vol.108
, Issue.7
, pp. 2435-2437
-
-
Scott, L.M.1
Scott, M.A.2
Campbell, P.J.3
Green, A.R.4
-
8
-
-
33845755386
-
Polycythemia vera is not initiated by JAK2V617F mutation
-
Nussenzveig RH, Swierczek SI, Jelinek J, et al. Polycythemia vera is not initiated by JAK2V617F mutation. Exp Hematol 2007;35:32-38.
-
(2007)
Exp Hematol
, vol.35
, pp. 32-38
-
-
Nussenzveig, R.H.1
Swierczek, S.I.2
Jelinek, J.3
-
9
-
-
53749103194
-
Phenotypic variability within the JAK2 V617F-positive MPD: Roles of progenitor cell and neutrophil allele burdens
-
Moliterno AR, Williams DM, Rogers O, et al. Phenotypic variability within the JAK2 V617F-positive MPD: roles of progenitor cell and neutrophil allele burdens. Exp Hematol 2008;36:1480-1486.
-
(2008)
Exp Hematol
, vol.36
, pp. 1480-1486
-
-
Moliterno, A.R.1
Williams, D.M.2
Rogers, O.3
-
10
-
-
77956439565
-
A prospective study of 338 patients with polycythemia vera: The impact of JAK2 (V617F) allele burden and leukocytosis on f brotic or leukemic disease transformation and vascular complications
-
Passamonti F, Rumi E, Pietra D, et al. A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on f brotic or leukemic disease transformation and vascular complications. Leukemia 2010;24:1574-1579.
-
(2010)
Leukemia
, vol.24
, pp. 1574-1579
-
-
Passamonti, F.1
Rumi, E.2
Pietra, D.3
-
11
-
-
78751706637
-
JAK2V617F allele burden in polycythemia vera correlates with grade of myelof brosis but is not substantially af ected by therapy
-
Silver RT, Vandris K, Wang YL, et al. JAK2V617F allele burden in polycythemia vera correlates with grade of myelof brosis, but is not substantially af ected by therapy. Leuk Res 2011;35:177-182.
-
(2011)
Leuk Res
, vol.35
, pp. 177-182
-
-
Silver, R.T.1
Vandris, K.2
Wang, Y.L.3
-
12
-
-
31544477194
-
V617F in polycythemia vera
-
DOI 10.1002/cncr.21645
-
Teferi A, Lasho TL, Schwager SM, et al. The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera. Cancer 2006;106:631-635. (Pubitemid 43157627)
-
(2006)
Cancer
, vol.106
, Issue.3
, pp. 631-635
-
-
Tefferi, A.1
Lasho, T.L.2
Schwager, S.M.3
Strand, J.S.4
Elliott, M.5
Mesa, R.6
Li, C.-Y.7
Wadleigh, M.8
Lee, S.J.9
Gilliland, D.G.10
-
13
-
-
34548131123
-
Bone marrow JAK2V617F allele burden and clinical correlates in polycythemia vera [17]
-
DOI 10.1038/sj.leu.2404724, PII 2404724
-
Teferi A, Strand JJ, Lasho TL, et al. Bone marrow JAK2V617F allele burden and clinical correlates in polycythemia vera. Leukemia 2007;21:2074-2075. (Pubitemid 47299994)
-
(2007)
Leukemia
, vol.21
, Issue.9
, pp. 2074-2075
-
-
Tefferi, A.1
Strand, J.J.2
Lasho, T.L.3
Knudson, R.A.4
Finke, C.M.5
Gangat, N.6
Pardanani, A.7
Hanson, C.A.8
Ketterling, R.P.9
-
14
-
-
34548136101
-
V617F allele burden
-
DOI 10.1038/sj.leu.2404854, PII 2404854
-
Vannucchi AM, Antonioli E, Guglielmelli P, et al. Prospective identif cation of high-risk polycythemia vera patients based on JAK2V617F allele burden. Leukemia 2007;21:1952-1959. (Pubitemid 47299969)
-
(2007)
Leukemia
, vol.21
, Issue.9
, pp. 1952-1959
-
-
Vannucchi, A.M.1
Antonioli, E.2
Guglielmelli, P.3
Longo, G.4
Pancrazzi, A.5
Ponziani, V.6
Bogani, C.7
Ferrini, P.R.8
Rambaldi, A.9
Guerini, V.10
Bosi, A.11
Barbui, T.12
-
15
-
-
0026649984
-
High incidence of myeloproliferative disorders in Ashkenazi Jews in Northern Israel
-
Chaiter Y, Brenner B, Aghai E, et al. High incidence of myeloproliferative disorders in Ashkenazi Jews in Northern Israel. Leuk Lymphoma 1992;7:251-255.
-
(1992)
Leuk Lymphoma
, vol.7
, pp. 251-255
-
-
Chaiter, Y.1
Brenner, B.2
Aghai, E.3
-
16
-
-
0031687645
-
Epidemiological data in polycythaemia vera: A study of 842 cases
-
Najean Y, Rain JD, Billotey C. Epidemiological data in polycythaemia vera: a study of 842 cases. Hematol Cell Ther 1998;40:159-165. (Pubitemid 28432315)
-
(1998)
Hematology and Cell Therapy
, vol.40
, Issue.4
, pp. 159-165
-
-
Najean, Y.1
Rain, J.-D.2
Billotey, C.3
-
17
-
-
39749192828
-
A new MALDI-TOF-based assay for monitoring JAK2 V617F mutation level in patients undergoing allogeneic stem cell transplantation (allo SCT) for classic myeloproliferative disorders (MPD)
-
DOI 10.1016/j.leukres.2007.07.003, PII S0145212607002895
-
Koren-Michowitz M, Shimoni A, Vivante A, et al. A new MALDI-TOF-based assay for monitoring JAK2 V617F mutation level in patients undergoing allogeneic stem cell transplantation (allo SCT) for classic myeloproliferative disorders (MPD). Leuk Res 2008;32:421-427. (Pubitemid 351295916)
-
(2008)
Leukemia Research
, vol.32
, Issue.3
, pp. 421-427
-
-
Koren-Michowitz, M.1
Shimoni, A.2
Vivante, A.3
Trakhtenbrot, L.4
Rechavi, G.5
Amariglio, N.6
Loewenthal, R.7
Nagler, A.8
Cohen, Y.9
-
18
-
-
54049126083
-
Relapse of postpolycythemia myelof brosis after allogeneic stem cell transplantation in a polycythemic phase: Successful treatment with donor lymphocyte infusion directed by quantitative PCR test for V617F-JAK2 mutation
-
Benjamini O, Koren-Michowitz M, Amariglio N, et al. Relapse of postpolycythemia myelof brosis after allogeneic stem cell transplantation in a polycythemic phase: successful treatment with donor lymphocyte infusion directed by quantitative PCR test for V617F-JAK2 mutation. Leukemia 2008;22:1961-1963.
-
(2008)
Leukemia
, vol.22
, pp. 1961-1963
-
-
Benjamini, O.1
Koren-Michowitz, M.2
Amariglio, N.3
-
19
-
-
42949094077
-
The presence of JAK2V617F in primary myelofibrosis or its allele burden in polycythemia vera predicts chemosensitivity to hydroxyurea
-
DOI 10.1002/ajh.21149
-
Sirhan S, Lasho TL, Hanson CA, et al. The presence of JAK2V617F in primary myelof brosis or its allele burden in polycythemia vera predicts chemosensitivity to hydroxyurea. Am J Hematol 2008;83:363-365. (Pubitemid 351614747)
-
(2008)
American Journal of Hematology
, vol.83
, Issue.5
, pp. 363-365
-
-
Sirhan, S.1
Lasho, T.L.2
Hanson, C.A.3
Mesa, R.A.4
Pardanani, A.5
Tefferi, A.6
-
20
-
-
68949211425
-
Postpolycythaemic myelof brosis: Frequency and risk factors for this complication in 116 patients
-
Alvarez-Larrán A, Bellosillo B, Martínez-Avilés L, et al. Postpolycythaemic myelof brosis: frequency and risk factors for this complication in 116 patients. Br J Haematol 2009;146:504-509.
-
(2009)
Br J Haematol
, vol.146
, pp. 504-509
-
-
Alvarez-Larrán, A.1
Bellosillo, B.2
Martínez-Avilés, L.3
-
21
-
-
76549109434
-
Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias
-
Abdel-Wahab O, Manshouri T, Patel J, et al. Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. Cancer Res 2010;70:447-452.
-
(2010)
Cancer Res
, vol.70
, pp. 447-452
-
-
Abdel-Wahab, O.1
Manshouri, T.2
Patel, J.3
-
22
-
-
34347394712
-
Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation
-
DOI 10.1182/blood-2006-12-062125
-
Theocharides A, Boissinot M, Girodon F, et al. Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. Blood 2007; 110:375-379. (Pubitemid 47026857)
-
(2007)
Blood
, vol.110
, Issue.1
, pp. 375-379
-
-
Theocharides, A.1
Boissinot, M.2
Girodon, F.3
Garand, R.4
Teo, S.-S.5
Lippert, E.6
Talmant, P.7
Tichelli, A.8
Hermouet, S.9
Skoda, R.C.10
|